Jochen Zisowsky

995 total citations
17 papers, 789 citations indexed

About

Jochen Zisowsky is a scholar working on Oncology, Physiology and Molecular Biology. According to data from OpenAlex, Jochen Zisowsky has authored 17 papers receiving a total of 789 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 4 papers in Physiology and 3 papers in Molecular Biology. Recurrent topics in Jochen Zisowsky's work include Drug Transport and Resistance Mechanisms (3 papers), Asthma and respiratory diseases (3 papers) and Eosinophilic Esophagitis (2 papers). Jochen Zisowsky is often cited by papers focused on Drug Transport and Resistance Mechanisms (3 papers), Asthma and respiratory diseases (3 papers) and Eosinophilic Esophagitis (2 papers). Jochen Zisowsky collaborates with scholars based in Switzerland, Germany and Croatia. Jochen Zisowsky's co-authors include Ulrich Jaehde, Eberhard Schlatter, Giuliano Ciarimboli, Thomas Ludwig, Hermann Koepsell, Maja Osmak, Hansjürgen Piechota, Detlef Lang, Jörg Haier and Hermann Pavenstädt and has published in prestigious journals such as SHILAP Revista de lepidopterología, American Journal Of Pathology and Annals of Oncology.

In The Last Decade

Jochen Zisowsky

17 papers receiving 775 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jochen Zisowsky Switzerland 9 341 286 219 165 66 17 789
Robin S. Goldstein United States 15 212 0.6× 171 0.6× 250 1.1× 123 0.7× 65 1.0× 38 925
Hansjürgen Piechota Germany 6 277 0.8× 169 0.6× 184 0.8× 134 0.8× 67 1.0× 14 565
Jason A. Sprowl United States 19 747 2.2× 315 1.1× 188 0.9× 295 1.8× 93 1.4× 34 1.2k
Katsuya Narumi Japan 17 226 0.7× 320 1.1× 119 0.5× 119 0.7× 104 1.6× 89 954
Sherif Y. Saad Saudi Arabia 13 140 0.4× 163 0.6× 276 1.3× 58 0.4× 56 0.8× 18 732
Camille Granvil United States 17 303 0.9× 414 1.4× 202 0.9× 57 0.3× 65 1.0× 34 1.0k
Ayako Furugen Japan 17 243 0.7× 327 1.1× 85 0.4× 117 0.7× 114 1.7× 90 931
Natsuko Watanabe Japan 21 86 0.3× 243 0.8× 255 1.2× 98 0.6× 75 1.1× 75 1.3k
Kinya Ohta Japan 17 344 1.0× 318 1.1× 38 0.2× 231 1.4× 62 0.9× 34 955
Serena Marchetti Netherlands 19 836 2.5× 577 2.0× 69 0.3× 151 0.9× 26 0.4× 48 1.4k

Countries citing papers authored by Jochen Zisowsky

Since Specialization
Citations

This map shows the geographic impact of Jochen Zisowsky's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jochen Zisowsky with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jochen Zisowsky more than expected).

Fields of papers citing papers by Jochen Zisowsky

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jochen Zisowsky. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jochen Zisowsky. The network helps show where Jochen Zisowsky may publish in the future.

Co-authorship network of co-authors of Jochen Zisowsky

This figure shows the co-authorship network connecting the top 25 collaborators of Jochen Zisowsky. A scholar is included among the top collaborators of Jochen Zisowsky based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jochen Zisowsky. Jochen Zisowsky is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Drenth, Henk‐Jan, et al.. (2020). Population pharmacokinetics of regorafenib in solid tumours: Exposure in clinical practice considering enterohepatic circulation and food intake. British Journal of Clinical Pharmacology. 86(12). 2362–2376. 18 indexed citations
2.
Grothey, Axel, Mihály Ruppert, Jochen Zisowsky, et al.. (2019). Exploration of efficacious alternative regorafenib regimens to manage hand-foot-skin-reaction (HFSR). Annals of Oncology. 30. v247–v247. 1 indexed citations
3.
Krause, Andreas, Jochen Zisowsky, & Jasper Dingemanse. (2018). Modeling of pharmacokinetics, efficacy, and hemodynamic effects of macitentan in patients with pulmonary arterial hypertension. Pulmonary Pharmacology & Therapeutics. 49. 140–146. 6 indexed citations
4.
Zisowsky, Jochen, Martine Géhin, Andjela Kusic‐Pajic, et al.. (2017). Pediatric Development of Bosentan Facilitated by Modeling and Simulation. Pediatric Drugs. 19(2). 121–130. 1 indexed citations
5.
Krause, Andreas, Jochen Zisowsky, Daniel S. Strasser, et al.. (2015). Pharmacokinetic/Pharmacodynamic Modelling of Receptor Internalization with CRTH2 Antagonists to Optimize Dose Selection. Clinical Pharmacokinetics. 55(7). 813–821. 9 indexed citations
6.
Géhin, Martine, Daniel S. Strasser, Jochen Zisowsky, et al.. (2015). A novel CRTH2 antagonist: Single‐ and multiple‐dose tolerability, pharmacokinetics, and pharmacodynamics of ACT‐453859 in healthy subjects. The Journal of Clinical Pharmacology. 55(7). 787–797. 15 indexed citations
7.
Strasser, Daniel S., Jochen Zisowsky, Martine Géhin, et al.. (2015). Development of a decision-making biomarker for CRTH2 antagonism in clinical studies. SHILAP Revista de lepidopterología. 2(4-5). 118–118. 7 indexed citations
8.
Zisowsky, Jochen, Eliane Fuseau, Shirin Bruderer, Andreas Krause, & Jasper Dingemanse. (2014). Challenges in collecting pharmacokinetic and pharmacodynamic information in an intensive care setting: PK/PD modelling of clazosentan in patients with aneurysmal subarachnoid haemorrhage. European Journal of Clinical Pharmacology. 70(4). 409–419. 5 indexed citations
9.
Krause, Andreas, Marc Lavielle, Christopher Kohl, et al.. (2013). Modeling the Two -Peak Phenomenon in Pharmacokinetics Using a Gut Passage Model with two Absorption Sites. 1 indexed citations
10.
Hoch, Matthias, et al.. (2012). Absolute Oral Bioavailability of Almorexant, a Dual Orexin Receptor Antagonist, in Healthy Human Subjects. Pharmacology. 89(1-2). 53–57. 13 indexed citations
11.
Zisowsky, Jochen, Andreas Krause, & Jasper Dingemanse. (2010). Drug Development for Pediatric Populations: Regulatory Aspects. Pharmaceutics. 2(4). 364–388. 73 indexed citations
12.
Thomas, Dirk, Jochen Zisowsky, & R. Horstmann. (2007). 195 LACOSAMIDE DEMONSTRATES NO POTENTIAL FOR QTC‐PROLONGATION. European Journal of Pain. 11(S1). 4 indexed citations
13.
Zisowsky, Jochen, et al.. (2006). Relevance of drug uptake and efflux for cisplatin sensitivity of tumor cells. Biochemical Pharmacology. 73(2). 298–307. 124 indexed citations
14.
Zisowsky, Jochen, et al.. (2005). The Raf kinase inhibitor BAY 43-9006 reduces cellular uptake of platinum compounds and cytotoxicity in human colorectal carcinoma cell lines. Anti-Cancer Drugs. 16(2). 129–136. 38 indexed citations
15.
Ciarimboli, Giuliano, Thomas Ludwig, Detlef Lang, et al.. (2005). Cisplatin Nephrotoxicity Is Critically Mediated via the Human Organic Cation Transporter 2. American Journal Of Pathology. 167(6). 1477–1484. 350 indexed citations
16.
Brozović, Anamaria, Gerhard Fritz, Markus Christmann, et al.. (2004). Long‐term activation of SAPK/JNK, p38 kinase and fas‐L expression by cisplatin is attenuated in human carcinoma cells that acquired drug resistance. International Journal of Cancer. 112(6). 974–985. 121 indexed citations
17.
Zisowsky, Jochen, et al.. (2003). Assessment of platinum sensitivity human tumor cells. International Journal of Clinical Pharmacology and Therapeutics. 41(12). 612–613. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Robin S. Goldstein Breakdown of academic impact, for papers by Hansjürgen Piechota Breakdown of academic impact, for papers by Jason A. Sprowl Breakdown of academic impact, for papers by Katsuya Narumi Breakdown of academic impact, for papers by Sherif Y. Saad Breakdown of academic impact, for papers by Camille Granvil Breakdown of academic impact, for papers by Ayako Furugen Breakdown of academic impact, for papers by Natsuko Watanabe Breakdown of academic impact, for papers by Kinya Ohta Breakdown of academic impact, for papers by Serena Marchetti
Rankless by CCL
2026